{"id":5662,"date":"2019-08-06T17:31:38","date_gmt":"2019-08-06T12:01:38","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5662"},"modified":"2024-09-17T16:28:09","modified_gmt":"2024-09-17T10:58:09","slug":"recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging","title":{"rendered":"FDA Approves Turalio; Sosei Heptares and Takeda Forge R&amp;D Partnership"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f1c5957c104\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f1c5957c104\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging\/#FDA_approves_first_Tenosynovial_giant_cell_tumour_treatment_Turalio_Pexidartinib\" >FDA approves first Tenosynovial\ngiant cell tumour treatment Turalio (Pexidartinib)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging\/#Sosei_Heptares_Takeda_enters_into_gastrointestinal_disease_R_D_pact\" >Sosei Heptares, Takeda enters into gastrointestinal disease R&amp;D\npact<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging\/#Hillrom_acquires_Breathe_Technologies_and_its_wearable_ventilator_for_USD_130M\" >Hillrom acquires Breathe Technologies and its wearable ventilator for USD 130M<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging\/#Exo_Imaging_raises_USD_35_Million_in_Series_B_financing_to_expand_Ultrasound_Platform\" >Exo Imaging raises USD 35 Million in Series B financing to expand\nUltrasound Platform<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\" id=\"h-fda-approves-first-tenosynovial-giant-cell-tumour-treatment-turalio-pexidartinib\"><span class=\"ez-toc-section\" id=\"FDA_approves_first_Tenosynovial_giant_cell_tumour_treatment_Turalio_Pexidartinib\"><\/span><strong>FDA approves first Tenosynovial\ngiant cell tumour treatment Turalio (Pexidartinib)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The US FDA has given its approval to <strong>Turalio <\/strong>(<strong>pexidartinib<\/strong>) capsules for the treatment of symptomatic <strong>tenosynovial giant cell <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastrointestinal-stromal-tumor-gist-market\">tumour<\/a><\/strong> (TGCT) associated with severe morbidity or functional limitations that surgery has failed to improve. The approval of <strong>Daiichi Sankyo<\/strong>&#8216;s Turalio was based on the results of the multi-centre international clinical trial of 120 patients. The trial showed that Turalio had statistically improved in overall response rate (ORR) to 38 per cent. 15% of the patients showed complete response and 23% showed partial response. Tenosynovial giant cell tumors are a group of rare, benign tumors in synovium bursae and tendon sheaths.<br>This the first-ever FDA-approved therapy to be available to treat rare tenosynovial giant cell <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tumor-market\">tumour<\/a>. The approval will bring relief to those patients for whom the only available option so far Surgery does not work. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-sosei-heptares-takeda-enters-into-gastrointestinal-disease-r-amp-d-pact\"><span class=\"ez-toc-section\" id=\"Sosei_Heptares_Takeda_enters_into_gastrointestinal_disease_R_D_pact\"><\/span><strong>Sosei Heptares, Takeda enters into gastrointestinal disease R&amp;D\npact<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Sosei Heptares<\/strong> and <strong>Takeda <\/strong>have decided to embark on a new strategic multi-target R&amp;D and commercialization collaboration to combine Sosei\u2019s structure-based drug design proficiencies with Takeda\u2019s therapeutic area expertise. The novel molecules will include small molecules and biologics that control <strong>G protein-coupled receptor<\/strong> (\u201cGPCR\u201d) targets, and will initially focus on novel, high-priority targets to address multiple gastrointestinal diseases. The partnership will advance the discovery of <strong>gut inflammation <\/strong>and <strong>motility disorders.<\/strong><br>Under the terms of the agreement, Sosei is eligible to receive up to<strong> USD 26 million upfront <\/strong>as research funding and future development, commercialization and net sales-based milestone payments may exceed <strong>USD 1.2 billion<\/strong>. Sosei is also entitled to tiered royalties on net sales of licensed products by Takeda, as well as Takeda receiving exclusive global rights to develop and commercialise therapeutic agents for each novel target through specified pharmacological approaches in the partnership. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-hillrom-acquires-breathe-technologies-and-its-wearable-ventilator-for-usd-130m\"><span class=\"ez-toc-section\" id=\"Hillrom_acquires_Breathe_Technologies_and_its_wearable_ventilator_for_USD_130M\"><\/span><strong>Hillrom acquires Breathe Technologies and its wearable ventilator for USD 130M<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Hillrom<\/strong>, a Medical technology company has signed a definitive agreement to buy<strong> Breathe Technologies<\/strong> for <strong>USD 130 Million <\/strong>in an all-cash transaction. The acquisition will help Hillrom to enhance its Respiratory Care portfolio, which includes The Vest, VitalCough, The MetaNeb System and Monarch Airway Clearance System. <br><strong>Breathe Technologies<\/strong> is a respiratory care solutions provider and manufacturer of a patented wearable, non-invasive ventilation technology that supports improved patient mobility. <br><strong>Breathe\u2019s Life2000<\/strong> is a volume-control, wearable, non-invasive mechanical ventilation system for a broad range of conditions including COPD, interstitial lung disease, restrictive thoracic disorder and post-lung-transplant rehab. The wearable will not confine patients to home since it can be independently used outside the home with an alternate pressure source.<br>Breathe\u2019s Life2000 added to Hillrom\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-acute-respiratory-syndrome-sars-coronavirus-infection-market\">respiratory<\/a> care portfolio, will ensure the companies to benefit from at least USD 30 million of net operating losses.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-exo-imaging-raises-usd-35-million-in-series-b-financing-to-expand-ultrasound-platform\"><span class=\"ez-toc-section\" id=\"Exo_Imaging_raises_USD_35_Million_in_Series_B_financing_to_expand_Ultrasound_Platform\"><\/span><strong>Exo Imaging raises USD 35 Million in Series B financing to expand\nUltrasound Platform <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Exo Imaging<\/strong> has raised<strong> USD 35 Million<\/strong> to advance the development of its Ultrasound system based on patented Piezoelectric Micromachined Ultrasonic Transducers (pMUT) technology and artificial intelligence (AI). The company has been successful in raising USD 50M since 2015, the year it was founded. The Series B financing was led by Intel Capital along with Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony Innovation Fund, and Wanxiang Healthcare Investments. <br>The company plans to help physicians by providing a single, handheld probe which can be used for observing the heart and other organs to imaging a person\u2019s vasculature or skeletal features in 3D.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA approves first Tenosynovial giant cell tumour treatment Turalio (Pexidartinib) The US FDA has given its approval to Turalio (pexidartinib) capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated with severe morbidity or functional limitations that surgery has failed to improve. The approval of Daiichi Sankyo&#8216;s Turalio was based on the results [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1635,704,554],"industry":[17226,17225],"therapeutic_areas":[17239,17228],"class_list":["post-5662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-daiichi-sankyo","tag-fda","tag-takeda","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Daiichi Sankyo, Sosei Heptares, Takeda<\/title>\n<meta name=\"description\" content=\"The FDA has given its approval to Turalio capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Daiichi Sankyo, Sosei Heptares, Takeda\" \/>\n<meta property=\"og:description\" content=\"The FDA has given its approval to Turalio capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-08-06T12:01:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:58:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180952\/Pharma-News.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Daiichi Sankyo, Sosei Heptares, Takeda","description":"The FDA has given its approval to Turalio capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Daiichi Sankyo, Sosei Heptares, Takeda","og_description":"The FDA has given its approval to Turalio capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-08-06T12:01:38+00:00","article_modified_time":"2024-09-17T10:58:09+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180952\/Pharma-News.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging","name":"Pharma News | Daiichi Sankyo, Sosei Heptares, Takeda","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180952\/Pharma-News.png","datePublished":"2019-08-06T12:01:38+00:00","dateModified":"2024-09-17T10:58:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The FDA has given its approval to Turalio capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-takeda-sosei-hillrom-breathe-tech-exo-imaging#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180952\/Pharma-News.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180952\/Pharma-News.png","width":750,"height":410,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180952\/Pharma-News-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Daiichi Sankyo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Daiichi Sankyo<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Aug 6, 2019","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Aug 6, 2019 5:31 pm","modified":"Updated on Sep 17, 2024 4:28 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5662"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5662\/revisions"}],"predecessor-version":[{"id":28295,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5662\/revisions\/28295"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5663"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5662"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5662"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}